

ASTRAZENECA PHARMA INDIA LIMITED

Regd. Office : 'Avishkar' Off Bellary Road, Hebbal, Bangalore 560 024

FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 30 SEPTEMBER 2006

Rs in lakhs (except for number of shares)

Sl No.	Particulars	Quarter ended 30.09.2006 (Unaudited)	Quarter ended 30.09.2005 (Unaudited)	Nine months ended 30.09.2006 (Unaudited)	Nine months ended 30.09.2005 (Unaudited)	Previous Accounting year ended 31.12.2005 (Audited)
1	Gross sales	7,450.69	6,205.78	20,984.14	17,677.17	24,327.13
2	Excise duty on sales	591.79	527.85	1,679.00	1,505.79	2,085.01
3	Net sales (1-2)	6,858.90	5,677.93	19,305.14	16,171.38	22,242.12
4	Service income	110.59	74.49	373.33	192.76	293.41
5	Other income	165.37	102.94	527.06	372.25	752.28
6	Total expenditure					
	(a) Decrease in finished goods and work-in-progress	(43.69)	60.96	78.66	508.35	315.45
	(b) Consumption of raw materials, packing materials and traded goods	2,526.53	1,682.49	6,728.93	4,733.71	7,212.64
	(c) Personnel costs	1,026.96	978.52	3,263.83	2,827.55	3,740.38
	(d) Other expenditure	1,540.25	1,321.58	4,451.54	3,644.34	5,016.82
7	Interest	0.92	0.97	2.82	4.48	5.45
8	Depreciation	147.44	123.63	426.33	359.87	519.46
9	Profit before tax (3+4+5-6-7-8)	1,936.45	1,687.21	5,253.42	4,658.09	6,477.61
10	Provision for tax, net	697.21	604.66	1,614.16	1,568.18	2,145.37
11	Provision for fringe benefit tax	21.00	65.65	116.10	110.00	103.00
12	Deferred tax (credit)/ charge	(18.21)	(36.37)	173.57	(30.50)	(76.57)
13	Net profit (9-10-11-12)	1,236.45	1,053.27	3,349.59	3,010.41	4,305.81
14	Paid-up equity share capital (Face value of Rs 2 per equity share)	500.00	500.00	500.00	500.00	500.00
15	Reserves excluding revaluation reserves (as per balance sheet of previous accounting year)	-	-	-	-	12,219.54
16	Basic and diluted earnings (Rs) per share (not annualised)	4.95	4.21	13.40	12.04	17.22
17	Aggregate of non-promoter shareholding					
	- Number of shares	2,500,050	2,500,050	2,500,050	2,500,050	2,500,050
	- Percentage of shareholding	10.0002%	10.0002%	10.0002%	10.0002%	10.0002%

Notes :

- 1 The above statement of financial results were reviewed by the Audit Committee on 28 October 2006 and approved by the Board of Directors of the Company at the meeting held on 28 October 2006.
- 2 The Company's sole business segment is Healthcare. The capital employed in this segment as on 30 September 2006 is Rs 16,069.13 lakhs (31 December 2005: Rs 12,719.54 lakhs).
- 3 Status of investor complaints : a) Pending as on 1 July 2006 - 1 b) Received during the quarter - 3 c) Disposed off during the quarter - 3 d) Pending as on 30 Sep 2006 - 1. There was only 1 investor complaint carried forward from the previous quarter, which pertains to dispute on ownership of shares.
- 4 The Board of Directors of the Company at their meeting held on 8 September 2006, approved the Scheme of Arrangement between the Company and its shareholders for issue of secured fully paid-up redeemable non-convertible bonus debentures from the Company's General Reserve, subject to the same being approved by the shareholders and creditors of the Company as required under Section 391 of the Companies Act, 1956 and the same being sanctioned by the Karnataka High Court under Section 391 of the said Act and obtaining of such other required approvals as may be necessary.
- 5 At the Extra-ordinary General Meeting held on 6 June 2006, the Shareholders of the Company approved the sub-division of equity shares. A share of face value of Rs 10 each has been subdivided to 5 equity shares of face value of Rs 2 each. The effective date for the sub-division was 22 June 2006. Consequently, the number of equity shares, disclosed and used for computation of earning per share has been adjusted for all the periods presented above.
- 6 Previous period figures have been regrouped/ reclassified, wherever necessary to conform to the current period's presentation.

**By Order of the Board of Directors
For ASTRAZENECA PHARMA INDIA LIMITED**